MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $125.90M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.72M
Average 0.98M
MGNX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
MacroGenics, Inc.NASDAQ: MGNX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $1.69M fell 4.7% year over year, in line with the -5.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.1% from the prior quarter. Over 3 fiscal years it compounded at -15.4% a year.
Context
- Depreciation & amortization amounted to 4.8% of revenue in FY2025, down 0.3 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -4.7% holds above the trailing-twelve-month pace of -5.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 7.17M USD
- Year-over-year change
- -4.9%
- 4-year CAGR
- -10.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.17M | -4.9% |
| FY2024 | 2024-12-31 | 7.54M | -21.8% |
| FY2023 | 2023-12-31 | 9.65M | -18.7% |
| FY2022 | 2022-12-31 | 11.87M | +5.4% |
| FY2021 | 2021-12-31 | 11.26M | — |
Depreciation & Amortization vs competitors
How MGNX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.1% is the 4th highest of 11, against a peer median of -16.0%.
- Depreciation & amortization amounts to 4.5% of revenue for MGNX, versus a peer median of 721.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.09M USD | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $3.64M USD | -3.9% | +6.3% | 364.3% | |
| LTM Mar 2026 | $1.45M USD | -11.2% | +13.6% | 1079.1% | |
| FY2025 | $704K USD | +6.7% | -11.9% | 1100.0% | |
| LTM Mar 2026 | $628K USD | -48.8% | -19.7% | — | |
| LTM Mar 2026 | €392.86K EUR | -17.3% | -11.1% | 1339.4% | |
| LTM Mar 2026 | $167K USD | -73.0% | -39.9% | 2.3% | |
| LTM Mar 2026 | $121K USD | -27.5% | -67.8% | — | |
| LTM Mar 2026 | $48.3K USD | +290.5% | +20.6% | — | |
| LTM Mar 2026 | $23.33K USD | -14.7% | +0.0% | 0.3% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $22K USD | -88.5% | -20.8% | — |
| Peer median (excluding MGNX) | — | -16.0% | -11.5% | 721.7% | |
Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.64M | 150.02M | 57.19M | 148.34M | 149.5M |
| Cost of Revenue | 2.65M | 7.38M | 8.22M | 12.3M | 43.18M |
| Gross Profit | 72.99M | 142.63M | 48.97M | 136.04M | 106.32M |
| Gross Margin | 96.5% | 95.1% | 85.6% | 91.7% | 71.1% |
| Research & Development | 214.58M | 207.03M | 166.58M | 177.19M | 140M |
| Selling, General & Admin | 63.01M | 58.95M | 52.19M | 71.05M | 39.16M |
| Operating Expenses | 275.79M | 264.05M | 217.22M | 246.62M | 179.16M |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 7.17M |
| EBITDA | (190.86M) | (107.89M) | 2.02M | (57.37M) | (59.61M) |
| EBITDA Margin | -252.3% | -71.9% | 3.5% | -38.7% | -39.9% |
| Operating Income | (202.8M) | (121.42M) | (168.24M) | (110.58M) | (72.84M) |
| Operating Margin | -268.1% | -80.9% | -294.2% | -74.5% | -48.7% |
| Interest Income | 680K | 1.7M | 9.69M | 9.42M | 3.4M |
| Interest Expense | 0 | 0 | 1.43M | 1.12M | 8.51M |
| Other Income / Expenses | 680K | 1.66M | 159.19M | 44.56M | (2.45M) |
| Income Before Tax | (202.12M) | (119.76M) | (9.06M) | (66.02M) | (75.29M) |
| Pre-Tax Margin | -267.2% | -79.8% | -15.8% | -44.5% | -50.4% |
| Income Tax Expense | 0 | 0 | 0 | 944K | (672K) |
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Net Margin | -267.2% | -79.8% | -15.8% | -45.1% | -49.9% |
| EPS (Basic) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| EPS (Diluted) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| Weighted Avg Shares | 59.94M | 61.41M | 61.93M | 62.62M | 63.16M |
| Weighted Avg Shares (Diluted) | 59.94M | 61.43M | 61.93M | 62.62M | 63.16M |
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$1.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.